(1) Objective: Bacterial resistance to conventional antibiotic therapy is an increasingly significant worldwide challenge to human health. The objective is to evaluate whether bacteriophage therapy could complement or be a viable alternative to conventional antibiotic therapy in critical cases of bacterial infection related to cardiothoracic surgery. (2) Methods: Since September 2015, eight patients with multi-drug resistant or especially recalcitrant Staphylococcus aureus, Enterococcus faecium, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli infections were treated with bacteriophage preparations as a therapy of last resort according to Article 37 of the Declaration of Helsinki. Patients had infections associated with immunosuppression after organ transplantation or had infections of vascular grafts, implanted medical devices, and surgical wounds. Individualized phage preparations were administered locally, orally, or via inhalation for different durations depending on the case. All patients remained on conventional antibiotics during bacteriophage treatment. (3) Results: Patients ranged in age from 13 to 66 years old (average 48.5 ± 16.7) with seven males and one female. Eradication of target bacteria was reached in seven of eight patients. No severe adverse side effects were observed. (4) Conclusions: Phage therapy can effectively treat bacterial infections related to cardiothoracic surgery when conventional antibiotic therapy fails.

Secondary infections of skin grafts pose a continuous problem in burn patients, very often leading to loss of transplanted skin grafts and making multiple surgical revisions necessary. We present a case report about persisting Pseudomonas aeruginosa infection in burn patients with known diabetes. The burn wounds in lower extremities required repeated debridements, multiple skin grafting attempts and finally an application of the dermal scaffold NovoSorb BTM. With these measures, we managed to undertake a successful reconstruction of infected burn defects and pre-vent an amputation. We concluded that the NovoSorb BTM could be seen as an additional promising tool in a burn surgery armamentarium. In cases where radical surgical wound decontamination is not possible without risking the loss of the limb, the application of NovoSorb BTM over a contaminated field can win extra time for topical infection treatment and additionally provide an excellent skin grafting ground.

(1) Background: Implant-associated bacterial infections are usually hard to treat conservatively due to the resistance and tolerance of the pathogens to conventional antimicrobial therapy. Bacterial colonization of vascular grafts may lead to life-threatening conditions such as sepsis. The objective of this study is to evaluate whether conventional antibiotics and bacteriophages can reliably prevent the bacterial colonization of vascular grafts. (2) Methods: Gram-positive and Gram-negative bacterial infections were simulated on samples of woven PET gelatin-impregnated grafts using Staphylococcus aureus and Escherichia coli strains, respectively. The ability to prevent colonization was evaluated for a mixture of broad-spectrum antibiotics, for strictly lytic species-specific bacteriophage strains, and for a combination of both. All the antimicrobial agents were conventionally tested in order to prove the sensitivity of the used bacterial strains. Furthermore, the substances were used in a liquid form or in combination with a fibrin glue. (3) Results: Despite their strictly lytic nature, the application of bacteriophages alone was not enough to protect the graft samples from both bacteria. The singular application of antibiotics, both with and without fibrin glue, showed a protective effect against S. aureus (0 CFU/cm²), but was not sufficient against E. coli without fibrin glue (M = 7.18 × 10⁴ CFU/cm²). In contrast, the application of a combination of antibiotics and phages showed complete eradication of both bacteria after a single inoculation. The fibrin glue hydrogel provided an increased protection against repetitive exposure to S. aureus (p = 0.05). (4) Conclusions: The application of antibacterial combinations of antibiotics and bacteriophages is an effective approach to the prevention of bacteria-induced vascular graft infections in clinical settings.

Introduction and importance: Multiple sclerosis is known to be associated with both sympathetic and parasympathetic cardiovascular autonomic dysregulation. Thus, patients with multiple sclerosis comorbidity represent a potentially challenging patient population in cardiac surgery, especially in on-pump operations. Despite this, very little is known about the hemodynamics during cardiopulmonary bypass and the optimal perfusion strategy for patients with multiple sclerosis undergoing cardiac operations. Case presentation: In this report, the authors describe a patient with relapsing-remitting multiple sclerosis, who underwent successful triple valve operation for aortic and mitral stenosis and tricuspid valve insufficiency. Distinct blood pressure variations in form of temporary pressure dips were noted during total cardiopulmonary bypass time as well as during the reperfusion period. Clinical discussion: Pressure variations were not attributable to surgical, pharmacological or perfusion-related manoeuvres. Thus, they most likely represent symptoms of cardiovascular autonomic dysregulation manifesting during cardiopulmonary bypass. In this patient, blood pressure variations terminated spontaneously and remained within an acceptable range without external correction. Conclusions: When treating patients with multiple sclerosis comorbidity, the potential pressure variability due to cardiovascular autonomic dysregulation should be taken into consideration to avoid increased blood pressure volatility due to overcorrection or undercorrection during cardiopulmonary bypass.

Background and Objectives: Optimal myocardial protection during minimally invasive aortic valve replacement (MIAVR) is debated. We compared four cardioplegia strategies. Materials and Methods: Consecutive MIAVR patients (January 2010–April 2025) at a single centre were analysed retrospectively. Cardioplegia regimens were Buckberg (n = 131), Calafiore (n = 153), Custodiol HTK (n = 146) and St Thomas’ (n = 113). Because substantial baseline imbalances were present in the unadjusted cohort, inverse probability of treatment weighting (IPTW) based on a multinomial propensity score was applied to achieve covariate balance between groups. IPTW was performed using a comprehensive propensity model that incorporated (1) baseline demographic and clinical characteristics, (2) anatomical factors, including bicuspid valve morphology. Procedural time variables were assessed in secondary sensitivity analyses. After IPTW application, all variables, including procedural times, achieved balance (ASMD < 0.1). Postoperative outcomes were then compared in this fully balanced pseudo-population. The Scheffé post hoc test was performed. Results: Groups were demographically comparable except for more bicuspid valves in Buckberg. New-onset paroxysmal atrial fibrillation occurred in 31.2% (Buckberg) and 26.5% (St Thomas’) versus 7.1% (Calafiore) and 2.0% (Custodiol) (p < 0.01). Respiratory insufficiency followed a similar pattern (p = 0.02). Intensive-care and hospital stay, major complications, left-ventricular ejection fraction, and 30-day mortality (0.6–3.0%) were equivalent. Bicuspid anatomy independently prolonged operative metrics but did not influence biomarkers. Conclusions: After comprehensive inverse probability weighting that balanced groups on all baseline characteristics and anatomical factors, Calafiore and Custodiol cardioplegia strategies maintained significantly lower rates of new-onset atrial fibrillation (9.3% and 3.8% vs. 28.5% for Buckberg, p < 0.01), reduced myocardial injury biomarker release (peak CK 520 and 510 vs. 920 U/L, p < 0.01), and decreased respiratory complications (7.8% and 8.1% vs. 16.2%, p = 0.01), while mortality, stroke, and resource utilisation measures remained comparable across strategies.

Background: Mitral valve replacement presents considerable challenges in the field of cardiothoracic surgery, particularly in patients aged 50 to 69, where the decision between bioprosthetic and mechanical valves is critical. Nevertheless, the optimal selection of prosthetic valves for candidates within this age-related gray zone remains inadequately defined, necessitating a thorough evaluation of long-term outcomes and associated risks. Objective: This study aims to assess mid-term outcomes of MIMVR in patients aged 50 to 69, comparing reoperation rates, prosthesis-related morbidity, and overall survival between bioprosthetic and mechanical valves. While many prior studies on valve choice in patients aged 50 to 69 years are derived from sternotomy cohorts, the novelty of our work lies in the exclusive focus on patients undergoing minimally invasive techniques. Methods: A retrospective analysis was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, including 172 patients aged 50–69 years who underwent minimally invasive mitral valve replacement via right minithoracotomy at a high-volume center in Germany between 2011 and 2023. Of the 172 patients, 95 underwent MIMVR using biological prostheses, while 77 received mechanical prostheses. Comprehensive data on demographics, surgical procedures, and postoperative complications, as well as long-term outcomes, were analyzed. Results: With a mean follow-up of 7.1 years, early outcomes revealed no significant differences in 30-day mortality (7.4% for bioprosthetic vs. 2.6% for mechanical; p = 0.06). There was no significant differences in all-cause mortality at 1 year (8.4% vs. 3.9%; p = 0.22), 3-year (9.5% vs. 7.8%; p = 0.69), and 5-year (13.7% vs. 10.4%; p = 0.19), or at the longest follow-up (13.7% vs. 10.4%; p = 0.51). Kaplan–Meier analysis showed no significant difference in long-term survival between the groups (p = 0.5427). Postoperative arrhythmia occurred significantly more frequently in the biologic group compared to the mechanical group (18.9% vs. 6.5%; p = 0.01). Conclusions: For patients aged 50–69 undergoing MIMVR using a bioprosthetic or mechanical valve, the mid-term survival and incidence of reoperation and re-hospitalization were comparable up to 7 years. This provides evidence supporting the safe application of the MICS approach with either valve type in this gray-zone age group.